Lefamulin
- Generic Name
- Lefamulin
- Brand Names
- Xenleta
- Drug Type
- Small Molecule
- Chemical Formula
- C28H45NO5S
- CAS Number
- 1061337-51-6
- Unique Ingredient Identifier
- 21904A5386
- Background
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synth...
- Indication
Lefamulin is indicated to treat adults diagnosed with community-acquired bacterial pneumonia (CABP) that is caused by susceptible bacteria. Its use should be reserved for confirmed susceptible organisms or a high probability of infection with susceptible organisms. The list of susceptible bacteria includes Streptococcus pneumoniae, Staphylococcus aureus (met...
- Associated Conditions
- Community acquired pneumonia caused by Streptococcus Pneumoniae, Haemophilus Influenzae, Methicillin-Sensitive Staphylococcus Aureus Infection, Legionella Pneumophila Infections, Mycoplasma pneumoniae infection, Chlamydophila Pneumoniae Infections
- Associated Therapies
- -
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 13
- Registration Number
- NCT05225805
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸University of Kansas School of Medicine, Kansas City, Kansas, United States
Lefamulin for M. Genitalium Treatment Failures
- Conditions
- Interventions
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT05111002
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 738
- Registration Number
- NCT02813694
- Locations
- 🇺🇸
Site 1060, Houston, Texas, United States
🇺🇸Site 1065, Fresno, California, United States
🇺🇸Site 1069, Houston, Texas, United States
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 551
- Registration Number
- NCT02559310
- Locations
- 🇦🇷
Site 3005, La Plata, Buenos Aires, Argentina
🇦🇷Site 3007, Córdoba, Argentina
🇦🇷Site 3001, Córdoba, Argentina
Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 20
- Registration Number
- NCT02557789
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.